ClinicalTrials.gg
RecruitingNCT06752681Updated Jul 22, 2026

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of DAY301 in Advanced or Metastatic Solid Tumors, sponsored by Day One Biopharmaceuticals, Inc.. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Day One Biopharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid tumors. The study comprises of 2 phases: Phase 1a dose escalation where participants will be administered DAY301 at escalating dose levels to assess safety and tolerability, and to determine the maximum tolerated dose (MTD) and/or the recommended dose (RD); In Phase 1b dose expansion, DAY301 will be evaluated in dose expansion cohorts.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors

Keywords

  • Advanced or metastatic solid tumors
  • Dose Escalation
  • Dose Expansion
  • DAY301
  • PTK7-Targeted Antibody-drug Conjugate
03

In context

Lead sponsor

Day One Biopharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of advanced or solid tumors of the following histologies:
  • Ovarian cancer
  • Esophageal squamous cell carcinoma
  • Triple-negative breast cancer
  • Non-small cell lung cancer
  • Small cell lung cancer
  • Head and neck squamous cell carcinoma
  • Cervical squamous cell carcinoma
  • Endometrial cancers

(Participants must have been previously treated with standard of care systemic therapy, have refused standard therapy, or have no standard therapy available).

  • Availability of tumor tissue sample (either an or a fresh biopsy) at screening
  • per , Version 1.1 (RECIST v1.1).
  • (ECOG) performance status of 0 or 1.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Prior use of PTK7 targeting treatment (Phase 1a) or prior use of PTK7 targeting treatments and/or topoisomerase 1 (TOP1) inhibitors (Phase 1b).
  • Phase 1b disease-specific exclusion criteria:

    1. Cohort 1: Neuroendocrine tumors or endometrial sarcoma (eg, stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas)
    2. Cohort 2: Nasopharyngeal primary tumors.
    3. Cohort 3: Ovarian cancer that progressed >6 months after the last dose of platinum-based chemotherapy (platinum-sensitive disease), or disease that did not respond (PR or complete response [CR]) to or progressed ≤91 days after the last dose of platinum-based chemotherapy (primary platinum- disease) .- History of small bowel obstruction requiring hospitalization within 3 months prior to the first dose of study treatment.
  • Ascites requiring frequent paracentesis (more often than approximately every 4 weeks) for symptomatic management, or new onset within 4 weeks prior to the first dose of study treatment. Patients with an indwelling catheter may be considered eligible, after consultation with the medical monitor.
  • Active or progressing or evidence of .
  • Persistent toxicities from previous systemic antineoplastic treatments of Grade >1, excluding alopecia and vitiligo.
  • Systemic antineoplastic therapy within five half-lives or 4 weeks, whichever is shorter, prior to first dose of study treatment, including agents.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    DAY301 intravenous (IV) infusion

    DAY301 will be administered at different dose levels in dose escalation and at the RD in dose expansion cohorts.

    Drug: DAY301

Interventions

  • DrugDAY301

    DAY301 will be administered as IV infusion

06

What researchers measure

Primary outcomes

  1. Phase 1a: Dose Escalation: Number of participants with reported Dose Limiting Toxicities (DLTs)

    To evaluate adverse events (AEs) considered dose limiting toxicities that occur in the first cycle of treatment (within a DLT observation period).

    Time frame: Within 21 days of first infusion (Day 1)

  2. Phase 1a: Dose Escalation: Number of participants with reported adverse events (AEs) and serious AEs (SAEs)

    The type, incidence, and severity of AEs and SAEs will be determined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: through the duration of treatment, up to approximately 12 months

  3. Phase 1a: Dose Escalation: Frequency of dose interruptions

    The frequency at which dose interruptions occur during dose-escalation

    Time frame: through the duration of treatment, up to approximately 12 months

  4. Phase 1a: Dose Escalation: Duration of dose interruptions

    The duration of dose interruptions that occur during dose-escalation.

    Time frame: through the duration of treatment, up to approximately 12 months

  5. Phase 1a: Dose Escalation: Frequency of dose reductions

    The frequency at which dose reductions occur during dose-escalation.

    Time frame: through the duration of treatment, up to approximately 12 months

  6. Phase 1a: Dose Escalation: Duration of dose reductions

    The duration of dose reductions that occur during dose-escalation.

    Time frame: through the duration of treatment, up to approximately 12 months

  7. Phase 1b: Dose Expansion: Objective response rate

    Objective response rate based on best overall response (BOR) will be assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

    Time frame: through the duration of treatment, up to approximately 12 months

  8. Phase 1b: Dose Expansion: Number of participants reporting AEs and SAEs

    The type, incidence, and severity of AEs and SAEs will be determined using the NCI CTCAE v5.0.

    Time frame: through the duration of treatment, up to approximately 12 months

  9. Phase 1b: Dose Expansion: Frequency of dose interruptions

    The frequency at which dose interruptions occur during dose-expansion.

    Time frame: through the duration of treatment, up to approximately 12 months

  10. Phase 1b: Dose Expansion: Duration of dose interruption

    The duration of dose interruptions that occur during dose-expansion.

    Time frame: through the duration of treatment, up to approximately 12 months

  11. Phase 1b: Dose Expansion: Frequency of dose reductions

    The frequency at which dose reductions occur during dose-expansion.

    Time frame: through the duration of treatment, up to approximately 12 months

  12. Phase 1b: Dose Expansion: Duration of dose reductions

    The duration of dose reductions that occur during dose-expansion.

    Time frame: through the duration of treatment, up to approximately 12 months

Secondary outcomes

  1. Phase 1a and Phase 1b: Maximum concentration (Cmax) of DAY301

    Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.

    Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months

  2. Phase 1a and Phase 1b: time to Cmax (Tmax) of DAY301

    Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.

    Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months

  3. Phase 1a and Phase 1b: area under the curve (AUC) of DAY301

    Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.

    Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months

  4. Phase 1a and Phase 1b: terminal half-life (t1/2) of DAY301

    Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.

    Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months

  5. Phase 1a Dose Escalation: Objective response rate

    Objective response rate based on BOR will be assessed by investigators according to RECIST v1.1.

    Time frame: through the duration of treatment, up to approximately 12 months

  6. Phase 1a and 1b: Clinical Benefit rate (CBR)

    Clinical Benefit rate will be assessed by investigators according to RECIST v1.1.

    Time frame: through the duration of treatment, up to approximately 12 months

  7. Phase 1a and 1b: duration of response (DOR)

    Duration of response will be assessed by investigators according to RECIST v1.1.

    Time frame: through the duration of treatment, up to approximately 12 months

  8. Phase 1a and 1b: time to response (TTR)

    Time to response will be assessed by investigators according to RECIST v1.1.

    Time frame: through the duration of treatment, up to approximately 12 months

  9. Phase 1a and 1b: Progression-free survival

    Progression-free survival will be assessed by investigators according to RECIST v1.1.

    Time frame: through the duration of treatment, up to approximately 12 months

  10. Phase 1b: Overall survival

    Overall survival will be assessed by investigators.

    Time frame: through the duration of treatment, up to approximately 12 months

  11. Phase 1a and 1b: Number of participants with positive antidrug antibodies (ADAs)

    Assessed by the measure of anti-drug antibodies in serum.

    Time frame: varying timepoints through the duration of treatment, up to approximately 12 months

07

Study locations

11 of 11 sites recruiting
  • Site: 001-058
    New Haven, Connecticut 06511, United States
    Recruiting
  • Site: 001-064
    Sarasota, Florida 34232, United States
    Recruiting
  • Site: 001-060
    Avon, Indiana 46202, United States
    Recruiting
  • Site: 001-059
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • Site: 001-039
    New York, New York 10065, United States
    Recruiting
  • Site: 001-073
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Site: 001-065
    Nashville, Tennessee 37203, United States
    Recruiting
  • Site: 001-069
    Houston, Texas 77030, United States
    Recruiting
  • Site: 001-057
    San Antonio, Texas 78240, United States
    Recruiting
  • Site: 011-013
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
  • Site: 011-005
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Dec 31, 2024
StartActual
Nov 18, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06752681
Lead sponsor
Day One Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Nov 18, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 22, 2026

Study contacts

Day One Clinical Trials Information
Contact
clinicaltrials@dayonebio.com
650-484-0899

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion